Literature DB >> 21494258

Prognosis in patients with MDS or AML and bone marrow blasts between 10% and 30% is not associated with blast counts but depends on cytogenetic and molecular genetic characteristics.

U Bacher, W Kern, T Alpermann, S Schnittger, A Kohlmann, H-U Klein, M Dugas, C Haferlach, T Haferlach.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21494258     DOI： 10.1038/leu.2011.80

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  2 in total

1.  Does a diagnosis of myelogenous leukemia require 20% marrow myeloblasts, and does <5% marrow myeloblasts represent a remission? The history and ambiguity of arbitrary diagnostic boundaries in the understanding of myelodysplasia.

Authors:  Marshall A Lichtman
Journal:  Oncologist       Date:  2013-08-27

2.  Normal karyotype mosaicism in adult AML patients with adverse-risk and undefined karyotype: preliminary report of treatment outcomes after hematopoietic stem cell transplantation.

Authors:  Jae-Ho Yoon; Hee-Je Kim; Seung-Hwan Shin; Seung-Ah Yahng; Byung-Sik Cho; Ki-Seong Eom; Yoo-Jin Kim; Seok Lee; Chang-Ki Min; Seok-Goo Cho; Dong-Wook Kim; Jong-Wook Lee; Woo-Sung Min; Chong-Won Park
Journal:  Int J Hematol       Date:  2013-04-25       Impact factor: 2.490
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.